Guangzhou, China
DM Intelligence, Ltd. is a technology company that leverages artificial intelligence in the field of new drug research and development. The company's proprietary platform, Artificial Intelligence Drug Discovery Platform (AI-DDP), integrates AI technologies to offer improved services to pharmaceutical companies, academic centers, and biotech firms. This innovative platform allows the optimization and design of small molecules with specific properties, as well as the analysis and prediction of candidate drugs' physicochemical, biological, and toxicological activities based on their structures.
Founded in 2018 and headquartered in China, DM Intelligence focuses on the AI industry. The company has not disclosed its last investment details nor the involved investors. With its AI solutions for small molecule drugs, the company aims to make significant advancements in the future of drug discovery and research.
